In vitro activity of daptomycin and comparator agents against Staphylococcus aureus isolates from intravenous drug users with right endocarditis

Infezioni in Medicina

Volumn 18, Issue 2, 2010, Pages 108-112

  Sanchez Porto, Antonio ^a   Casanova Roman, Manuel ^a   Casas Ciria, Javier ^a   Santaella, Maria Jose ^a   Sanchez Morenilla, Immaculada ^a   Eiros Bouza, Jose Maria ^b  

^a Hospital of La Linea   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Daptomycin; Endocarditis; Staphyococcus aureus

Indexed keywords

CEFOXITIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; RIFAMPICIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; DRUG ACTIVITY; EPSILOMETER TEST; HUMAN; IN VITRO STUDY; INTRAVENOUS DRUG ABUSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; CELL MEMBRANE; COLONY COUNT, MICROBIAL; DAPTOMYCIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; REAGENT STRIPS; STAPHYLOCOCCUS AUREUS; SUBSTANCE ABUSE, INTRAVENOUS; VANCOMYCIN RESISTANCE;

EID: 77954981808     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Eisenstein B.I. Lipopeptides, focusing on daptomycin, for the treatment of gram-positive infections. Expert Opin. Investig. Drugs 13, 1159-1169, 2004.
2. Fuchs P.C., Barry A.L., Brown S.D. Daptomycin susceptibility tests: interpretative criteria, quality control, and effect of calcium on in vitro tests. Diagn. Microbiol. Infect. Dis. 38, 51-58, 2000.
3. Jevitt L.A., Thorne G.M., Traczewski M.M., et al. Multicenter evaluation of the E-test and Disk Diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. J. Clin. Microbiol. 44 (9), 3098-3104, 2006.
4. Streit J.M., Jones R.N., Sader H.S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J. Antimicrob. Chemother. 53, 669-674, 2004.
5. Bannerman T.L., Peacock S.J. 2007. Staphylococcus, Micrococcus, and other catalase-positive cocci that grow aerobically. In: Murray RM, Barron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. Washington DC: ASM Press. p. 390-411.
6. th edition, M7-A7. Wayne, PA: CLSI; 2006.
7. th informational supplement, M100-S18. Wayne, PA: CLSI; 2008.
8. Fowler V.G. Jr, Miro J.M., Hoen B., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293, 3012-3021, 2005. (Pubitemid 40965071)
9. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents 27, 300-302, 2006.
10. Fowler V.G. Jr, Boucher H.W., Corey R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 335, 653-665, 2006.
11. Soriano A., Marco F., Martinez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46,193-200, 2008.
12. Sader H.S., Fritsche T.R., Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 50, 2330-2336, 2006.
13. Tsuji B.T., Rybak M.J. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49, 2735-2745, 2005.
14. Miro J.M., García de la Maria C., Armero Y., et al. The addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009 Jul 20. [Epub ahead of print].
15. Sader H.S., Streit J.M., Fritsche T.R., Jones R.N. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin. Microbiol. Infect. 12, 844-852, 2006.
16. Castanheira M., Jones R.N., Sader H.S. Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America. Diagn. Microbiol. Infect. Dis. 61, 235-239, 2008.
17. Picazo J.J., Betriu C., Culebras E., Rodriguez-Avial I., Gomez M., Lopez F. Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers. Diagn. Microbiol. Infect. Dis. 64, 448-451, 2009.
18. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 1079-1082, 2006.
19. Gallon O., Guillet-Caruba C., Lamy B., Laurent F., Doucet-Populaire F., Decousser J.W. In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: data from two nationwide studies. Eur. J. Clin. Microbiol. Infect. Dis. 2009 Jun 6. [Epub ahead of print].
20. Garau J., Bouza E., Chastre J., Gudiol F., Harbarth S. Management of methicillin-resistant Staphylococcus aureus infections. Clin. Microbiol. Infect 15, 125-36, 2009.
21. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111, e394-434, 2005.
22. Torres-Tortosa M., de Cueto M., Vergara A., et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 13, 559-64, 1994.